At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
ABT-450/r/ABT-267 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-Arm, Phase 2 Study to Evaluate the Combination of ABT-450/r/ABT-267 and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Hepatitis C Virus (HCV) Infection Taking Methadone or Buprenorphine
In Brief
A Phase 2 clinical trial evaluating ABT-450/r/ABT-267, ABT-333, and 1 other intervention for Chronic Hepatitis C Infection and Chronic Hepatitis C. Completed, enrolled 38 participants.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults taking methadone or buprenorphine ± naloxone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Infection, Chronic Hepatitis C
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedJul 2013
Primary CompletionDec 2013
Study CompletionSep 2014
TodayJul 2026
First PostedJul 30, 2013
Enrollment StartApr 1, 2013
Primary CompletionDec 1, 2013
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.9 years ago
Interventions
ABT-450/r/ABT-267drug
Tablet; ABT-450 coformulated with ritonavir and ABT-267
ABT-333drug
Tablet
Ribavirin (RBV)drug
Tablet